DDInter1055 DDInter1676
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
Levofloxacin {u} (Compound) upregulates {v} (Gene) CPVL
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Levofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Levofloxacin {u} (Compound) downregulates {v} (Gene) TRIB3
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dysphagia
Levofloxacin (Compound) resembles Enoxacin (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound)
Levofloxacin (Compound) binds ABCB1 (Gene)
Levofloxacin (Compound) upregulates CPVL (Gene)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Levofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Levofloxacin (Compound) downregulates TRIB3 (Gene)
Levofloxacin (Compound) causes Dysphagia (Side Effect)